{"doi":"10.1016/j.jinf.2024.106258","title":"IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C","abstract":"BACKGROUND: Shorter duration therapy for hepatitis C virus (HCV) infection might reduce treatment costs and increase the number of patients treated and cured. We determined factors associated with treatment response after an 8-week sofosbuvir-based therapy and developed a simple model to predict an individual's likelihood of treatment success. METHODS: Among 2907 patients who received ledipasvir/sofosbuvir for 8 weeks, we determined failure rates by demographic and clinical characteristics, and IFNL4-∆G/TT genotype. We estimated the average IFNL4 genotype-related treatment failure rate in major ancestry groups by applying our IFNL4 genotype results to genotype distributions from reference populations. We created a treatment response model based on three personal characteristics. RESULTS: copies/mL (2.0%) or HCV genotype-1B infection (2.6%). In a model based on ancestry, age and sex, the predicted probability of treatment failure ranged from 0.5% among females of East Asian ancestry <50 years of age to 8.5% among males of African ancestry age ≥65 years. CONCLUSION: Applying this algorithm at the point-of-care might facilitate HCV elimination, especially in low- and middle-income countries.","journal":"Journal of Infection","year":2024,"id":451711,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9509,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1273611,"name":"David Witt","orcid":null,"position":1,"is_corresponding":false},{"id":1273113,"name":"Varun Saxena","orcid":"0000-0003-1278-3455","position":2,"is_corresponding":false},{"id":1040008,"name":"Kerry Grace Morrissey","orcid":"0000-0002-0988-4610","position":3,"is_corresponding":false},{"id":859323,"name":"Sabrina Chen","orcid":"0009-0009-2805-9059","position":4,"is_corresponding":false},{"id":821200,"name":"Francine Baker","orcid":"0000-0003-3133-3652","position":5,"is_corresponding":false},{"id":237171,"name":"Ludmila Prokunina‐Olsson","orcid":"0000-0002-9622-2091","position":6,"is_corresponding":false},{"id":282490,"name":"Ruth M. Pfeiffer","orcid":"0000-0001-7791-2698","position":7,"is_corresponding":false},{"id":1273114,"name":"Jennifer B. Lai","orcid":"0000-0002-3418-4800","position":8,"is_corresponding":false},{"id":24060,"name":"Thomas R. OʼBrien","orcid":"0000-0003-0003-6065","position":0,"is_corresponding":true}],"reference_count":30,"raw_metadata":null,"created_at":"2026-07-19T02:02:45.951080Z","pmid":"39216831","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}